Technical Data
Cadherin 11 (OB-Cadherin, Osteoblast, CDH11)
Cadherin-11, a mesenchymal adherin,2 is localized to the cell membrane in a detergent-soluble complex, where it associates with a-and b-catenin , and may facilitate tumor cell invasion and metastasis.4 Cadherin-11 exists as two alternatively spliced forms, cadherin-11 (OB cadherin) and cadherin-11 variant (OB-cadherin-2). The variant form is a truncated protein with an unusual cytoplasmic domain, that is not present in other cadherins.3 Both wildtype and variant form of cadherin-11 are expressed in invasive and poorly differentiated breast cancer cell lines.4 A study has shown that the presence of cadherin-11 splice variant promotes the invasion of cadherin-11 positive breast cancer cells.1

Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
ELISA: 0.1-1ug/ml
Western Blot: 1-3ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
storglyMay be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile glycerol (40-50%), aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay
PabIgGAffinity Purified
100ug4C (-20C Glycerol)Blue IceHumanRabbit
0.25 mg/ml
Synthetic peptide derived from the C-terminal region of the human Cadherin-11 Variant (OB-cadherin-2) protein.
Purified by immunoaffinity chromatography.
Supplied as a liquid in PBS, 0.09% sodium azide.
Recognizes the C terminal region of human Cadherin-11 Variant protein. On Western blots, it identi es a single band at ~85kD. Western blots using wildtype cadherin-11 transfected HEK293 cells yielded negative results. Reactivity has been con rmed with Cadherin-11 Variant transfected human HEK293 cell lysates.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Feltes CM, et al. Cancer Res 62(22): 6688-6697, 2002. 2. Hoffmann I, et al. Dev Biol 169(1): 337-346, 1995. 3. Okazaki M, et al. J Biol Chem 269(16): 12092-12098, 1994. 4. Pishvaian MJ et al. Cancer Res 59(4): 947-952, 1999.